<DOC>
	<DOCNO>NCT02699892</DOCNO>
	<brief_summary>This Phase IV post-marketing , non-interventional , open label , non-comparative prospective study examine efficacy safety rituximab participant previously receive rituximab term everyday medical practice . Efficacy safety rituximab determine 24 week receive first infusion , 24 week second infusion repeat course treatment ( participant receive another course rituximab ) 24 week third infusion repeat course treatment ( participant receive third course rituximab ) . Protocol specify criterion initiation treatment rituximab procedure infusion rituximab . Rituximab administer discretion treat physician accord approved label .</brief_summary>
	<brief_title>Study Examine Efficacy Safety Rituximab Participants With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Participants receive rituximab longer 4 week start monitoring</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>